Responses to crizotinib in a patient with c-ros oncogene 1, receptor tyrosine kinase-positive advanced lung adenocarcinoma: A case report

Oncology Letters

Volumn 8, Issue 6, 2014, Pages 2624-2626

  Zhang, Na ^a,b   Yang, Jin Ji ^a   Zhang, Xu Chao ^a   Xie, Zhi ^a   Wang, Bin Chao ^a   Tu, Hai Yan ^a   Jiang, Ben Yuan ^a   Wu, Yi Long ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Crizotinib; Gene rearrangements; Immunohistochemistry; Non small cell lung cancer; Partial responses; Receptor tyrosine kinase 1

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; C ROS ONCOGENE 1 RECEPTOR TYROSINE KINASE; CISPLATIN; CRIZOTINIB; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4; EPIDERMAL GROWTH FACTOR RECEPTOR; PEMETREXED; PEPTIDES AND PROTEINS; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ABNORMAL RESPIRATORY SOUND; ADULT; AMPLIFICATION REFRACTORY MUTATION SYSTEM; ARTICLE; ATELECTASIS; CANCER CHEMOTHERAPY; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG RESPONSE; DYSPNEA; FIBEROPTIC BRONCHOSCOPY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; GENETIC PROCEDURES; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG DISEASE; LUNG GROUND GLASS OPACITY; MALE; PULMONARY VALVE STENOSIS;

EID: 84908052634     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2571     Document Type: Article

References (9)

1. Sholl LM, Sun H, Butaney M, et al: ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas. Am J Surg Pathol 37: 1441-1449, 2013.
2. Ou SI, Bang Y, Camidge DR, et al: Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). J Clin Oncol 31: 8032, 2013.
3. Kang W, Tong JH, Chan AW, et al: Yes-associated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis. Clin Cancer Res 17: 2130-2139, 2011.
4. Davies KD, Le AT, Theodoro MF, et al: Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res 18: 4570-4579, 2012.
5. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009.
6. McLeer Florin A, Mescam-Mancini L, Moro-Sibilot D, et al: Detection of ROS1 translocations in triple-negative lung adenocarcinomas. J Clin Oncol 31: 8099, 2013.
7. Ou SH, Tan J, Yen Y, and Soo RA: ROS1 as a ‘druggable’ receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway. Expert Rev Anticancer Ther 12: 447-456, 2012.
8. Shaw AT, Camidge DR, Engelman JA, et al: Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. J Clin Oncol 30: 7508, 2012.
9. Cai W, Li X, Su C, et al: ROS1 fusions in Chinese patients with non-small-cell lung cancer. Ann Oncol 24: 1822-1827, 2013.